Demonstration of an anti‐hyperalgesic effect of a novel pan‐Trk inhibitor PF‐06273340 in a battery of human evoked pain models

No abstract is available for this paper.

• Publication year

  2018

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2018-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bcp.13448PMID 29178434PMCID PMC5777446
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Demonstration of an anti‐hyperalgesic effect of a novel pan‐Trk inhibitor PF‐06273340 in a battery of human evoked pain models

  2018cited by this paper
• The use of a battery of pain models to detect analgesic properties of compounds: a two‐part four‐way crossover study

  2017cited by this paper
• The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain.

  2016cited by this paper
• Progress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activity

  2016cited by this paper
• Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

  2016cited by this paper
• NEUROPATHIC PAIN SECTION Original Research Article Exploring the Role of Tanezumab as a Novel Treatment for the Relief of Neuropathic Pain

  2016cited by this paper
• Selective inhibition of tropomyosin-receptor-kinase A (TrkA) reduces pain and joint damage in two rat models of inflammatory arthritis

  2016cited by this paper
• When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program

  2016cited by this paper
• Neurotrophins and Neuropathic Pain: Role in Pathobiology

  2015cited by this paper
• The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

  2015cited by this paper
• THE USE OF A BATTERY OF PAIN MODELS TO DETECT ANALGESIC PROPERTIES OF COMPOUNDS : A TWO-PART, FOUR-WAY, RANDOMISED, PLACEBO-CONTROLLED, CROSSOVER STUDY

  2015cited by this paper
• Brain-derived neurotrophic factor as a driving force behind neuroplasticity in neuropathic and central sensitization pain: a new therapeutic target?

  2015cited by this paper
• The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors

  2015cited by this paper
• Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain.

  2015cited by this paper
• Efficacy and Safety of Intravenous Tanezumab for the Symptomatic Treatment of Osteoarthritis: 2 Randomized Controlled Trials versus Naproxen

  2014cited by this paper
• Long‐term safety and effectiveness of tanezumab as treatment for chronic low back pain

  2014cited by this paper
• Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology

  2013cited by this paper
• Local Gene Expression Changes after UV-Irradiation of Human Skin

  2012cited by this paper
• Treatment of chronic non-cancer pain.

  2011cited by this paper
• Antagonism of Nerve Growth Factor-TrkA Signaling and the Relief of Pain

  2011cited by this paper
• The use of baseline covariates in crossover studies.

  2010cited by this paper
• NGF induces non‐inflammatory localized and lasting mechanical and thermal hypersensitivity in human skin

  2010cited by this paper
• Neurotrophins: mediators and modulators of pain.

  2006cited by this paper
• p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia.

  2002cited by this paper
• Modulation of ultraviolet‐induced hyperalgesia and cytokine upregulation by interleukins 10 and 13

  2000cited by this paper

• Zincke-Imine-Based Peripheral Editing of 2-Arylpyridines to Access 3-Acylpyridines.

  2025cites this paper
• Mechanism-based nonopioid analgesic targets

  2025cites this paper
• Established and emerging roles of protein kinases in regulating primary sensory neurons in injury-and inflammation-associated pain

  2025cites this paper
• Randomized, placebo‐controlled study on the effects of intravenous GSK3858279 (anti‐CCL17) on a battery of evoked pain tests in healthy participants

  2024cites this paper
• Challenges and Opportunities for In Vitro–In Vivo Extrapolation of Aldehyde Oxidase-Mediated Clearance: Toward a Roadmap for Quantitative Translation

  2023cites this paper
• Drug clearance by aldehyde oxidase: can we avoid clinical failure?

  2022cites this paper
• A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a Highly Selective NaV1.8 Inhibitor, in Healthy Male Adults

  2021cites this paper
• Methodology and applicability of the human contact burn injury model: A systematic review

  2021cites this paper
• First‐in‐human trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of STR‐324, a dual enkephalinase inhibitor for pain management

  2021cites this paper
• Analgesic drug development: proof-of-mechanism and proof-of-concept in early phase clinical studies

  2021cites this paper
• Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.

  2021cites this paper
• Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases.

  2021cites this paper
• Challenging the challenge: a randomized controlled trial evaluating the inflammatory response and pain perception of healthy volunteers after single-dose LPS administration, as a potential model for inflammatory pain in early-phase drug development.

  2020cites this paper
• Does In Vitro Potency Predict Clinically Efficacious Concentrations?

  2020cites this paper
• Synthetic Routes for Venetoclax at Different Stages of Development

  2019cites this paper
• Optimization of an Azaindazole Series of CCR1 Antagonists and Development of a Semicontinuous-Flow Synthesis

  2019cites this paper
• Lack of Detection of the Analgesic Properties of PF‐05089771, a Selective Nav1.7 Inhibitor, Using a Battery of Pain Models in Healthy Subjects

  2019cites this paper
• The ultraviolet B inflammation model: Postinflammatory hyperpigmentation and validation of a reduced UVB exposure paradigm for inducing hyperalgesia in healthy subjects

  2019cites this paper
• Quantitative Systems Pharmacology and Empirical Models: Friends or Foes?

  2019cites this paper
• Discovery and Early Development of Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors

  2019cites this paper
• Discovery and Development of the First Antibody–Antibiotic Conjugate Linker-Drug

  2019cites this paper
• From Discovery to Market Readiness: The Research and Development of the β-Sparing Phosphatidylinositol 3-Kinase Inhibitor Taselisib

  2019cites this paper
• Discovery and Development of Non-Covalent, Reversible Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853)

  2019cites this paper
• Discovery and Development of Lorlatinib: A Macrocyclic Inhibitor of EML4-ALK for the Treatment of NSCLC

  2019cites this paper
• The Discovery of the Nav1.7 Inhibitor GDC-0276 and Development of an Efficient Large-Scale Synthesis

  2019cites this paper
• The Discovery and Chemical Development of PF-06273340: A Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor for Pain

  2019cites this paper
• Foreword

  2019cites this paper
• Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2

  2019cites this paper
• Analgesic potential of PF-06372865, an a 2/ a 3/ a 5 subtype-selective GABA A partial agonist, in humans

  2019cites this paper
• Rational Design to Large-Scale Synthesis: Development of GSK8175 for the Treatment of Hepatitis C Virus Infection

  2019cites this paper
• Discovery and Development of AMG 333: A TRPM8 Antagonist for Migraine

  2019cites this paper
• Title, Copyright, Foreword

  2019cites this paper
• Editors’ Biographies

  2019cites this paper
• Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABAA partial agonist, in humans.

  2019cites this paper
• Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain.

  2018cites this paper
• Demonstration of an anti‐hyperalgesic effect of a novel pan‐Trk inhibitor PF‐06273340 in a battery of human evoked pain models

  2018cites this paper
• R esearch Advance in NGF in Neuropathic Pain and Related Drugs

  year unknowncites this paper